The Chicago Tribune spoke to families and advocates seeking better treatment options for Duchenne muscular dystrophy as part of their coverage of Marathon Pharmaceuticals, a company working to earn U.S. approval for a Duchenne muscular dystrophy treatment.
A Northbrook company said it has won fast-track status for approval of a drug that could become the first in the United States to treat Duchenne muscular dystrophy, a fatal muscle disease found most often in boys...
U.S. Food and Drug Administration approval is eagerly awaited by people such as Ellen Wagner, whose son, Tim, was diagnosed at 2 with Duchenne. The McHenry mom began ordering deflazacort from the United Kingdom after the physician treating her son wrote a prescription. Its use in the U.S. is legal because there is no other approved treatment for Duchenne in the country.
Read the full story